Trials / No Longer Available
No Longer AvailableNCT00076960
Compassionate Use of Stanate (TM) [Stannsoporfin]
Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company · Industry
- Sex
- All
- Age
- 12 Hours – 1 Week
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to make Stanate (TM) \[stannsoporfin, tin-mesoporphyrin\] available to infants who meet the following criteria: 1. the infant has a very high level of bilirubin without an adequate clinical response to phototherapy; 2. the infant requires an exchange transfusion; and 3. the family refuses to allow the administration of blood products, particularly on religious grounds, such as within the Jehovah's Witness community.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Stanate (TM) [stannsoporfin, tin-mesoporphyrin] | Treatment with 4.5 mg/kg |
Timeline
- First posted
- 2004-02-10
- Last updated
- 2019-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00076960. Inclusion in this directory is not an endorsement.